MedPath

Compare Tolerability of an Overnight Switch to Gradual Switch Between Two Different Forms of Depakote

Phase 4
Conditions
Epilepsy
Behavioral Disturbance
Registration Number
NCT00312676
Lead Sponsor
Veterans Affairs Medical Center, Miami
Brief Summary

The hypothesis is that the characteristics of extended release Depakote will allow overnight conversion of immediate release to extended release form of Depakote. This has been tested successfully in younger patients but not in individuals over the age of 60. We will include individuals between 60 and 80 years old.

Detailed Description

Twenty patients will be randomily assigned to convert overnight (10 pts) or over six days (10 pts). Side effects will be formally evaluated by the UKU side effect rating scal which will be done 7 days before conversion (day -7), the day of conversion (day 0)and then at the start of days +2, +7 and +14. This investigator conducting the evaluation will be blinded to the conversion status of the patient. Secondary measures to be obtained will be a Quality of Life measure (QOLIE-89) on Day 0 and +14. Plasma samples will be obtained on Day 0 and +14 before dosing for total and free valproic blood level.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
20
Inclusion Criteria
  • 60 yo and older on stable dose of valproate (Depakote DR)
Exclusion Criteria
  • Unstable neurolgical, medical or psychiatric disorder

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Between group comparisons of GI and CNS side effect burden
Secondary Outcome Measures
NameTimeMethod
Between group comparison of Quality of Life as measured bye the QOLIE-89
Between group comparison of trough Total and Free valproic acid serum levels

Trial Locations

Locations (1)

Miami VA Medical Center

🇺🇸

Miami, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath